ArticleThe Journal of investigative dermatology2011
TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier.
Article in The Journal of investigative dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 221 citations in OpenAlex.
- Pink lotus flower (Biomedical reports · 2026Article
- SFPQ/S100A8 complex induces filaggrin deficiency via selective autophagy and JNK phosphorylation in atopic dermatitis.Cell communication and signaling : CCS · 2026Article
- Divergent Paths: A Comprehensive Review of Mechanisms and Clinical Implications in Atopic Dermatitis and Psoriasis.Allergy · 2026Review
- Regulation of Imiquimod-Induced Mouse Psoriasis Development via Apoptosis Signal-Regulating Kinase 1 Potentially by Antagonizing Aryl Hydrocarbon Receptor Expression.Current issues in molecular biology · 2026Article
- Anti-Inflammatory and Barrier-Related Effects ofInternational journal of molecular sciences · 2026Article
- Plant extract mixture shows anti-inflammatory and barrier-strengthening effects and activates aryl hydrocarbon receptor in a 2D psoriasis model.Scientific reports · 2026Article
- Article
- Comparative analysis of candidate gene expression in Asian atopic dermatitis and psoriasis: identification of shared and distinct molecular features.Frontiers in medicine · 2026Article
- Skin Protection Effects of Lactobacillus paragasseri HN910 Lysate and the Role of Alanine.Probiotics and antimicrobial proteins · 2026Article
- Skin barrier dysfunction and correlation with the onset and progression of psoriasis.Frontiers in immunology · 2026Review
- Jaungo-based herbal complex regulates psoriasis-associated macrophage-keratinocyte inflammatory axis.Frontiers in pharmacology · 2026Article
- CD4Frontiers in immunology · 2026Article
- Genome-wide cross-trait analysis of heterogeneous outcomes in early life atopic dermatitis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Article
- Sesamol regulates AQP3 and HAS2 via MAPK signaling for skin barrier protection an in vitro and molecular docking study.Scientific reports · 2025Article
- The Anti-Inflammatory and Skin Barrier Function Recovery Effects ofInternational journal of molecular sciences · 2025Article
- Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis.International journal of molecular sciences · 2025Article
- The Role of Oxidative Stress in Skin Disorders Associated with Alcohol Dependency and Antioxidant Therapies.Molecules (Basel, Switzerland) · 2025Review
- History-dependent switch-like differentiation of keratinocytes in response to skin barrier damage.PLoS computational biology · 2025Article
- Safety Profile ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Histone Modifications and DNA Methylation in Psoriasis: A Cellular Perspective.Clinical reviews in allergy & immunology · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedGuttman, Emma [corrected to Guttman-Yassky, Emma]
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Filaggrin (FLG), loricrin (LOR), and involucrin are important epidermal barrier proteins. As psoriasis is characterized by overexpression of tumor necrosis factor-α (TNF-α) and impaired skin barrier, we investigated the expression of skin barrier proteins in psoriasis patients and whether their expression was modulated by TNF-α. The expression of FLG and LOR was found to be decreased in lesional and non-lesional skin of psoriasis patients. A correlation was found between the expression of TNF-α and epidermal barrier proteins in psoriasis. TNF-α was found to modulate the expression of FLG and LOR via a c-Jun N-terminal kinase-dependent pathway. Importantly, we report that clinical treatment of psoriasis patients with a TNF-α antagonist results in significant enhancement of epidermal barrier protein expression. Our current study suggests that TNF inhibits barrier protein expression, and TNF-α antagonists may contribute to clinical improvement in patients with psoriasis by improving barrier protein expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.